Cirrus Pharmaceuticals, a Kemwell company, which is a 100% services oriented company providing pharmaceutical contract development and manufacturing services, will be investing in a flexible cGMP suite in its facility in North Carolina’s Research Triangle Park.

“With this investment, we are bringing our customers a new service from our U.S. facility,” said Ninad Deshpanday, president of R&D at Kemwell. “We will offer our clients cGMP manufacturing services for many dosage forms including inhalation, liquids, topicals and oral solids. This service will enable our clients to enter clinic faster. We have completed the design phase and expect the suite to be ready to service customers by April 2015.”

Today, Kemwell’s R&D division employs over 175 scientists worldwide and provides services ranging from formulation development, analytical development and validation to clinical trial manufacturing. The team has experience working on early stage development programs for NCEs, ANDAs, 505(b)(2) and product life cycle management projects for various customers across the world, including virtual, small and big pharma. With the addition of the cGMP suite, Cirrus will be able to extend its offerings in the U.S. from contract development to manufacturing.